---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-23-000042"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:44:01.477375+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q1 net product revenue $2.8M; net loss $80.1M as ZORYVE launch builds

## Summary
- Net product revenue of $2.8M from ZORYVE; unit demand nearly doubled QoQ.
- Net loss $80.1M ($1.31/share) vs $64.3M ($1.27) in Q1 2022; SG&A rose to $42.9M.
- Cash, equivalents, and marketable securities $333.3M; operating cash burn $80.3M in Q1.
- Health Canada approved ZORYVE for plaque psoriasis; launch expected in coming weeks.
- FDA accepted NDA for roflumilast foam (seborrheic dermatitis); target action date Dec 16, 2023.

## SEC filing metadata
- accession: 0001787306-23-000042
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000042/0001787306-23-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000042/arqt-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-23-000042
- JSON: https://secwatch.observer/filing/0001787306-23-000042.json
- Plain text: https://secwatch.observer/filing/0001787306-23-000042.txt

## Key facts
- Earnings Releases
  Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $2.8 million.
  - Period: the quarter ended March 31, 2023
  - Revenue: $2.8 million
  - Result: reported results
  source text: by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update • Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarter • Continued expansion of commercial payer coverage
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000042/0001787306-23-000042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.